Morgan Stanley Citius Pharmaceuticals, Inc. Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,500 shares of CTXR stock, worth $4,695. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,500
Previous 9,740
84.6%
Holding current value
$4,695
Previous $5,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding CTXR
# of Institutions
61Shares Held
23.7MCall Options Held
83.1KPut Options Held
32.1K-
Armistice Capital, LLC New York, NY7.28MShares$22.8 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.44MShares$20.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$5.88 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.81MShares$5.65 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.16MShares$3.63 Million0.0% of portfolio
About Citius Pharmaceuticals, Inc.
- Ticker CTXR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 146,130,000
- Market Cap $457M
- Description
- Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...